Foghorn Therapeutics Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
FHTX$1.90-6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Income Loss
(In thousands, except share and per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Collaboration revenue | $83,543 | $8,153 | $102,882 | $21,662 |
| Operating expenses: | ||||
| Research and development | 18,836 | 20,002 | 55,618 | 63,420 |
| General and administrative | 5,796 | 6,652 | 18,731 | 20,753 |
| Restructuring costs | 2,272 | — | 2,272 | — |
| Total operating expenses | 26,904 | 26,654 | 76,621 | 84,173 |
| Income (loss) from operations | 56,639 | (18,501) | 26,261 | (62,511) |
| Other income, net: | ||||
| Interest income | 1,527 | 2,032 | 4,878 | 7,033 |
| Other income (expense), net | (16) | 620 | (55) | 2,859 |
| Total other income, net | 1,511 | 2,652 | 4,823 | 9,892 |
| Net income (loss) | $58,150 | $(15,849) | $31,084 | $(52,619) |
| Net income (loss) per share attributable to common stockholders—basic | $0.81 | $(0.25) | $0.44 | $(0.84) |
| Weighted average common shares outstanding—basic | 71,460,569 | 63,029,293 | 70,550,389 | 62,952,723 |
| Net income (loss) per share attributable to common stockholders—diluted | $0.80 | $(0.25) | $0.43 | $(0.84) |
| Weighted average common shares outstanding—diluted | 72,590,923 | 63,029,293 | 71,573,572 | 62,952,723 |
| Comprehensive income (loss): | ||||
| Net income (loss) | $58,150 | $(15,849) | $31,084 | $(52,619) |
| Other comprehensive income (loss): | ||||
| Unrealized gains (losses) on marketable securities | 11 | 68 | (147) | (111) |
| Total other comprehensive income (loss) | 11 | 68 | (147) | (111) |
| Total comprehensive income (loss) | $58,161 | $(15,781) | $30,937 | $(52,730) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.